Treatment with sorafenib, the MEK inhibitor U0126 and the BRAF‐specific inhibitor PLX4720 did not change the mitochondrial localization or anti‐apoptotic activity of BRAF V600E in thyroid cancer.15 Here, BRAF is linked to thyroid gland carcinoma.